Register Login

Aquestive Therapeutics Inc (AQST)

  • Event
  • June 08, 2022, 20:22 UTC

(10% Negative) Aquestive Therapeutics, Inc. (AQST) Announces Delay in advisor Trials for a registered direct offering Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 5:42 a.m.

    📋 Aquestive Therapeutics, Inc. (AQST) - Clinical Trial Update

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 16:22:06

    Event Type: Clinical Trial Update

    Event Details:

    Aquestive Therapeutics Inc (AQST) Announces Clinical Trial Update Aquestive Therapeutics Inc (AQST) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: advisor, agent
    • Diseases/Conditions: a registered direct offering, general corporate purposes
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Brookline Capital Markets

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aquestive Therapeutics Inc
    • CIK: 0001398733
    • Ticker Symbol: AQST
    • Period End Date: 2022-06-06
    • Document Type: 8-K

Search

News categories